Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt No Debt
ATRS's Cash to Debt is ranked higher than
96% of the 181 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.42 vs. ATRS: No Debt )
Ranked among companies with meaningful Cash to Debt only.
ATRS' s 10-Year Cash to Debt Range
Min: 0.01  Med: 10000.00 Max: No Debt
Current: No Debt
Equity to Asset 0.60
ATRS's Equity to Asset is ranked higher than
53% of the 168 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 0.59 vs. ATRS: 0.60 )
Ranked among companies with meaningful Equity to Asset only.
ATRS' s 10-Year Equity to Asset Range
Min: -4.09  Med: 0.59 Max: 0.95
Current: 0.6
-4.09
0.95
Interest Coverage No Debt
ATRS's Interest Coverage is ranked higher than
94% of the 104 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 53.79 vs. ATRS: No Debt )
Ranked among companies with meaningful Interest Coverage only.
ATRS' s 10-Year Interest Coverage Range
Min: 9999.99  Med: 10000.00 Max: 9999.99
Current: No Debt
F-Score: 3
Z-Score: 1.42
M-Score: -2.77
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating margin (%) -111.46
ATRS's Operating margin (%) is ranked lower than
90% of the 178 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.07 vs. ATRS: -111.46 )
Ranked among companies with meaningful Operating margin (%) only.
ATRS' s 10-Year Operating margin (%) Range
Min: -1709.11  Med: -193.93 Max: -26.96
Current: -111.46
-1709.11
-26.96
Net-margin (%) -111.80
ATRS's Net-margin (%) is ranked lower than
91% of the 178 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.95 vs. ATRS: -111.80 )
Ranked among companies with meaningful Net-margin (%) only.
ATRS' s 10-Year Net-margin (%) Range
Min: -1728.74  Med: -189.78 Max: -26.66
Current: -111.8
-1728.74
-26.66
ROE (%) -67.37
ATRS's ROE (%) is ranked lower than
91% of the 173 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.63 vs. ATRS: -67.37 )
Ranked among companies with meaningful ROE (%) only.
ATRS' s 10-Year ROE (%) Range
Min: -6822.87  Med: -102.58 Max: -19.42
Current: -67.37
-6822.87
-19.42
ROA (%) -44.46
ATRS's ROA (%) is ranked lower than
91% of the 183 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.88 vs. ATRS: -44.46 )
Ranked among companies with meaningful ROA (%) only.
ATRS' s 10-Year ROA (%) Range
Min: -530.86  Med: -59.93 Max: -15.37
Current: -44.46
-530.86
-15.37
ROC (Joel Greenblatt) (%) -331.48
ATRS's ROC (Joel Greenblatt) (%) is ranked lower than
91% of the 180 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 11.56 vs. ATRS: -331.48 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
ATRS' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -2034.35  Med: -912.74 Max: -394.95
Current: -331.48
-2034.35
-394.95
Revenue Growth (3Y)(%) 5.60
ATRS's Revenue Growth (3Y)(%) is ranked higher than
54% of the 147 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.00 vs. ATRS: 5.60 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
ATRS' s 10-Year Revenue Growth (3Y)(%) Range
Min: -63.4  Med: 8.15 Max: 89.8
Current: 5.6
-63.4
89.8
EBITDA Growth (3Y)(%) 86.60
ATRS's EBITDA Growth (3Y)(%) is ranked higher than
97% of the 127 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 7.90 vs. ATRS: 86.60 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
ATRS' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -41.9  Med: -13.10 Max: 86.6
Current: 86.6
-41.9
86.6
EPS Growth (3Y)(%) 75.40
ATRS's EPS Growth (3Y)(%) is ranked higher than
94% of the 124 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.70 vs. ATRS: 75.40 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
ATRS' s 10-Year EPS Growth (3Y)(%) Range
Min: -58.1  Med: -12.95 Max: 75.4
Current: 75.4
-58.1
75.4
» ATRS's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2014

ATRS Guru Trades in Q2 2014

First Eagle Investment 20,000 sh (unchged)
» More
Q3 2014

ATRS Guru Trades in Q3 2014

Jim Simons 145,728 sh (New)
First Eagle Investment 20,000 sh (unchged)
» More
Q4 2014

ATRS Guru Trades in Q4 2014

First Eagle Investment 20,000 sh (unchged)
Jim Simons 85,970 sh (-41.01%)
» More
Q1 2015

ATRS Guru Trades in Q1 2015

First Eagle Investment 20,000 sh (unchged)
Jim Simons Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with ATRS

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
Forward P/E 29.67
ATRS's Forward P/E is ranked lower than
80% of the 75 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 21.98 vs. ATRS: 29.67 )
Ranked among companies with meaningful Forward P/E only.
N/A
P/B 7.93
ATRS's P/B is ranked lower than
87% of the 170 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.89 vs. ATRS: 7.93 )
Ranked among companies with meaningful P/B only.
ATRS' s 10-Year P/B Range
Min: 2.5  Med: 8.26 Max: 77.5
Current: 7.93
2.5
77.5
P/S 9.46
ATRS's P/S is ranked lower than
85% of the 181 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.70 vs. ATRS: 9.46 )
Ranked among companies with meaningful P/S only.
ATRS' s 10-Year P/S Range
Min: 3.56  Med: 13.13 Max: 36
Current: 9.46
3.56
36
Current Ratio 1.97
ATRS's Current Ratio is ranked lower than
61% of the 174 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.56 vs. ATRS: 1.97 )
Ranked among companies with meaningful Current Ratio only.
ATRS' s 10-Year Current Ratio Range
Min: 0.11  Med: 3.10 Max: 17.17
Current: 1.97
0.11
17.17
Quick Ratio 1.69
ATRS's Quick Ratio is ranked higher than
51% of the 174 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.68 vs. ATRS: 1.69 )
Ranked among companies with meaningful Quick Ratio only.
ATRS' s 10-Year Quick Ratio Range
Min: 0.09  Med: 2.91 Max: 16.5
Current: 1.69
0.09
16.5
Days Inventory 187.04
ATRS's Days Inventory is ranked lower than
75% of the 173 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 125.77 vs. ATRS: 187.04 )
Ranked among companies with meaningful Days Inventory only.
ATRS' s 10-Year Days Inventory Range
Min: 11.13  Med: 36.33 Max: 200.11
Current: 187.04
11.13
200.11
Days Sales Outstanding 51.81
ATRS's Days Sales Outstanding is ranked higher than
69% of the 153 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 62.15 vs. ATRS: 51.81 )
Ranked among companies with meaningful Days Sales Outstanding only.
ATRS' s 10-Year Days Sales Outstanding Range
Min: 15.98  Med: 48.34 Max: 266.58
Current: 51.81
15.98
266.58

Valuation & Return

vs
industry
vs
history
Price/Net Cash 107.00
ATRS's Price/Net Cash is ranked lower than
93% of the 44 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 12.26 vs. ATRS: 107.00 )
Ranked among companies with meaningful Price/Net Cash only.
ATRS' s 10-Year Price/Net Cash Range
Min: 1.18  Med: 12.77 Max: 135.5
Current: 107
1.18
135.5
Price/Net Current Asset Value 15.29
ATRS's Price/Net Current Asset Value is ranked lower than
69% of the 108 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 7.96 vs. ATRS: 15.29 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
ATRS' s 10-Year Price/Net Current Asset Value Range
Min: 0.89  Med: 9.16 Max: 54
Current: 15.29
0.89
54
Price/Tangible Book 8.92
ATRS's Price/Tangible Book is ranked lower than
77% of the 151 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.32 vs. ATRS: 8.92 )
Ranked among companies with meaningful Price/Tangible Book only.
ATRS' s 10-Year Price/Tangible Book Range
Min: 0.62  Med: 7.50 Max: 44.5
Current: 8.92
0.62
44.5
Price/Median PS Value 0.74
ATRS's Price/Median PS Value is ranked higher than
82% of the 162 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.24 vs. ATRS: 0.74 )
Ranked among companies with meaningful Price/Median PS Value only.
ATRS' s 10-Year Price/Median PS Value Range
Min: 0.08  Med: 0.81 Max: 2.49
Current: 0.74
0.08
2.49
Earnings Yield (Greenblatt) (%) -12.98
ATRS's Earnings Yield (Greenblatt) (%) is ranked lower than
82% of the 177 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.90 vs. ATRS: -12.98 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
ATRS' s 10-Year Earnings Yield (Greenblatt) (%) Range
Min: -14.5  Med: 0.00 Max: 0
Current: -12.98
-14.5
0

Business Description

Industry: Medical Instruments & Equipment » Medical Instruments & Supplies
Compare:WST, BAX, COV, TMO, COO » details
Traded in other countries:MJC.Germany,
Antares Pharma Inc was incorporated on February 1979. The Company is a specialty pharmaceutical company. It is engaged in developing and commercializing self-administered parenteral pharmaceutical products and technologies. It develops & manufactures novel, pressure-assisted injectors, with and without needles, which allow patients to self-inject drugs. The Company has developed variations of the needle-free injector by adding a small shielded needle to a pre-filled, single-use disposable injector, called the Vibex pressure assisted auto injection system. This system is an alternative to the needle-free system for use with injectable drugs in unit dose containers and is suitable for branded and generic injectables. It also developed a disposable multi-dose pen injector for use with standard cartridges. The Company developed the Vibex auto injector for its product OTREXUP. The Company has launched OTREXUP injection, subcutaneous methotrexate for once weekly self-administration with an easy-to-use, single dose, disposable auto injector. The Company is conducting clinical studies of Vibex QS T, for testosterone replacement therapy. It is also developing VIBEX Sumatriptan for the acute treatment of migraines. The Company's development projects include VIBEX epinephrine, an exenatide multi-dose pen, and another undisclosed multi-dose pen. The Company also makes a reusable, needle-free, spring-action injector device known as the Tjet and Zomajet, which is marketed for use with human growth hormone. The Company also has a portfolio of gel-based products inclduing Gelnique for the treatment of overactive bladder. The Company sells its proprietary reusable needle-free injectors and related disposable products to pharmaceutical partners and through medical product distributors. The Company's competitors include Pfizer, NovoNordisk, Warner-Chilcott, Novartis, Mylan, Roxane, Bedford Labs, Hospira, and Accord Healthcare. Any potential products discovered, developed and manufactured by the Company must comply with comprehensive regulation by the FDA in the U.S. and by comparable authorities in other countries.
» More Articles for ATRS

Headlines

Articles On GuruFocus.com
Weekly CFO Sells Highlight: ATRS, DENN, TTWO, JAH, ACET Jun 11 2013 

More From Other Websites
Deerfield Management Trims Holding In Antares Pharma Inc (ATRS) Just Before Disastrous Setback Jun 17 2015
Antares Pharma to Present at the JMP Securities Life Sciences Conference Jun 16 2015
Antares Pharma to Present at the JMP Securities Life Sciences Conference Jun 16 2015
Earnings Estimates Moving Higher for Antares (ATRS): Time to Buy? - Tale of the Tape Jun 08 2015
Sell These 7 Health Care Supplies Companies Now Jun 04 2015
ANTARES PHARMA, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Submission of... Jun 03 2015
Analyst Offers Top US Growth Stock Calls for This Week Jun 02 2015
Antares Pharma Announces Additional Update to QuickShot Testosterone Program Jun 02 2015
ANTARES PHARMA, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits Jun 01 2015
Antares Pharma Announces Additional Update to QuickShot Testosterone Program Jun 01 2015
Top Analyst Upgrades and Downgrades: Antares, Michael Kors, Palo Alto, Ralph Lauren, Chipotle,... May 28 2015
Antares Pharma to Present at the Jefferies 2015 Global Healthcare Conference May 28 2015
Antares Pharma to Present at the Jefferies 2015 Global Healthcare Conference May 28 2015
Coverage initiated on Antares Pharma by Jefferies May 28 2015
ANTARES PHARMA, INC. Financials May 20 2015
10-Q for Antares Pharma, Inc. May 13 2015
Antares Pharma Announces Closing of Public Offering of Common Stock May 11 2015
Antares Pharma Announces Closing of Public Offering of Common Stock May 11 2015
Antares Pharma Reports First Quarter 2015 Financial and Operating Results May 11 2015
Antares Pharma reports 1Q loss May 11 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK